Keywords
How to Cite
Abstract
Recurrences of serous borderline tumors (PCOS) are quite rare and, as a result, have not been sufficiently studied and presented in the literature. Despite the obvious relative «benignity» of borderline tumors, the course and prognosis of recurrent PCOS may be unfavorable. The article describes the reasons influencing the development of recurrence of PCOS, presents various options for recurrence of PCOS, methods of their treatment. This publication highlights the factors influencing the effectiveness of treatment, survival and prognosis of the disease. The article is illustrated with a rare clinical observation of multiple recurrence of PCOS with a favorable outcome.
References
Taylor HC. Malignant and semimalignant tumors of the ovary // Surg. Gynecol. Obstet. 1929;48:204–230.
Kurman RJ, Сarcanqiu ML, Herrington CS, Young RH. WHO Classificaihion of Tumours of Female Reproductive Organs. Fourth Edition. IARS: Lyon, 2014.
Lodhi S, Najam S, Pervez S. DNA ploidy analysis of borderline epithelial ovarian tumours // J. Pak. Med. Assoc. 2000;50(10):349–351.
Scully R.E, Young RH, Clement PB. Tumor like lesions. Tumors of the overy and maldeveloped gonads, fallopian tube and broad ligament. Washington: Armed Forces Institute of Pathology, 1998:443–444.
Shih IeM, R.J. Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges // Clin. Cancer Res. 2005;11(20):7273–7279.
Shim SH, Kim SN, Jung PS et al. Impact of surgical staging on prognosis in patients with borderline ovarian tumours: a meta-analysis // Eur. J. Cancer. 2016;54:84–95.
Acs G. Serous and mucinous borderline (low malignant potential) tumors of the ovary // Am J Clin Pathol. 2005;123(Suppl.):13–57.
Lenhard MS, Mitterer S, Kümper C. Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort // Eur J Obstet Gynecol Reprod Biol. 2009;145:189–94. https: // doi: 10.1016/j.ejogrb.2009.04.031 PMID: 19477060
Lalwani N, Shanbhogue AK, Vikram R. Current update on borderline ovarian neoplasms AJR // Am J Roentgenol. 2010;194(2):330–6. https: // doi: 10.2214/AJR.09.3936 PMID: 20093592
Seidman JD, Horkayne-Szakaly I, Haiba M. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin // Int J Gynecol Pathol. 2004;23:41–44. https: // doi: 10.1097/01.pgp.0000101080.35393.16
Sherman ME, Mink PJ, Curtis R. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis // Cancer. 2004;100:1045–52. https: // doi: 10.1002/cncr.20080 PMID: 14983501
Ayhan A, Akarin R, Develioglu O et al. Borderline epithelial ovarian tumors // Aust. N.Z.J. Obstet. Gynecol. 1991;31(2):174–176.
Goldman TL, Chalas E, Chumas J et al. Management of borderline tumors of the ovary // South. Med. J. 1993;86(4):423–425.
Jimenez AM, Miralles Pi RM, Sanchez AE et al. Ovarian tumors of low malignant potential (borderline). A retrospective study of 31 cases // Eur. J. Gynaec. Oncol. 1994;15(4):300–304.
Jones MB. Borderline ovarian tumors: current concepts for prognostic factors and clinical management // Clin Obstet Gynecol. 2006;49(3):517–25. https: // doi: 10.1097/00003081-200609000-00011 PMID: 16885658
Lalwani N, Shanbhogue AK, Vikram R. Current update on borderline ovarian neoplasms // AJR Am J Roentgenol. 2010;194(2):330–6. https: // doi: 10.2214/AJR.09.3936 PMID: 20093592
Bostwick DG, Tazelaar HD, Ballon SC. Ovarian epithelial tumors of borderline malignancy: a clinical and pathologic study of 109 cases // Cancer. 1983;58:2052–64 PMID: 3756820
Leake JF, Currie JL, Rosenshein NB. Long-term follow-up of serous ovarian tumors of low malignant potential // Gynecol Oncol. 1992;47:150–8. https: // doi: 10.1016/0090-8258(92)90099-5 PMID: 1468692
Riman T, Dickman PW, Nilsson S. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case — control study // Gynecol Oncol. 2001;83:575–85. https: // doi: 10.1006/gyno.2001.6451 PMID: 11733975
Nikrui N (1981) Survey of clinical behavior of patients with borderline tumors of the ovary // Gynecol Oncol. 1981;12:107–19. https: // doi: 10.1016/0090-8258(81)90102-5 PMID: 6268484
Ortiz BH, Ailawadi M, Colitti C et al. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors // Cancer Res. 2001;61(19):7264–7267.
Du Bois A, Ewald-Riegler N, du Bois O, Harter P. Borderline tumors of the ovary — a systematic review // Geburtsh. Frauenheilk. 2009;69:807–833.
Du Bois A, Trillsch F, Mahner S et al. Management of borderline ovarian tumors // Annals of Oncology. 2016;27 (Suppl. 1):i20–i22. https: // doi: 10.1093/annonc/mdw090
Trillsch F, Mahner S, JRuetzel JD et al. Clinical management of borderline ovarian tumors // Expert Rev. Anticancer Ther. 2010;10(7):1115–1124.
Trope C, Davidson B, Paulsen T et al. Diagnosis and treatment of borderline ovarian neoplasms «thestate of the art» // Eur. J. Gynaecol. Oncol. 2009;30(5):471–482.
Crispens MA, Bodurka D, Deavers M et al. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential // Obstet. Gynecol. 2002;99(1):3–10.
Давыдова И.Ю. Серозные пограничные опухоли яичников (клинико-морфологические особенности, лечение, прогноз). Дис. … д-ра мед. наук. М., 2018.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021